Catechol-O-Methyltransferase and Genetic Variation Under Hemizygosity
نویسندگان
چکیده
منابع مشابه
Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk.
Because catechol-O-methyltransferase (COMT) catalyzes the addition of methyl groups to stabilize catechol estrogens that may induce DNA damage, genetic variants could influence breast cancer risk. To comprehensively characterize genetic variation in this gene, we selected haplotype-tagging single nucleotide polymorphisms (htSNP) in COMT. A total of 11 htSNPs (including COMT Val(158)Met) were se...
متن کاملCatechol O-methyltransferase genetic polymorphism in panic disorder.
OBJECTIVE The authors examined the distribution of catechol O-methyltransferase (COMT) genotypes in patients with panic disorder as well as the relationship between a COMT polymorphism and the clinical characteristics of these patients. METHOD Fifty-one patients with panic disorder and 45 healthy comparison subjects were tested for a genetic polymorphism of COMT. Clinical variables were asses...
متن کاملCatechol-O-methyltransferase and Parkinson's disease.
Parkinson's disease (PD) is one of the main causes of neurological disability in the elderly. Levodopa is the gold standard for treating this disease, but chronic levodopa therapy is complicated by motor fluctuation and dyskinesia. The catechol-O-methyltransferase (COMT) inhibitors represent a new class of antiparkinsonian drugs. When coadministered with levodopa/decarboxylase inhibitor, 2 COMT...
متن کاملMetabolism of catechol estrogens by erythrocyte catechol-O methyltransferase.
Fishman and Tulchinsky (1) present evidence that the catechol estrogen 2hydroxyestrone suppresses serum prolactin in normal ovulatory young women. However, in 3 of the 12 subjects studied the authors were unable to suppress serum prolactin and suggested that prolactin response to 2-hydroxyestrone is subjectand not time-dependent. In a study designed to evaluate the kinetics of catechol estrogen...
متن کاملCatechol-O-Methyltransferase in Parkinson’s Disease
The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer and colleagues in 1961 and Barbeau and colleagues in 1962, and in its ultimately successful form by Cotzias and colleagues in 1967, still represents the defining landmark in the treatment of PD (1–3). This dramatic advance was preceded by methodical basic laboratory research in the late 1950s and early 196...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biological Psychiatry
سال: 2014
ISSN: 0006-3223
DOI: 10.1016/j.biopsych.2013.12.011